A bipartisan group of senators sponsored a bill this
week—the Biologic Patent Transparency Act, S. 659—aimed
at making patent information associated with biologics easier to
identify and easing the approval process for biosimilar
manufacturers encountering patent roadblocks.
The bill tracks some key provisions of the Hatch-Waxman Act.
Notably, it requires the holders of an approved biologic product to
submit a list of patents associated with the biologic within 30
days of approval. If a new patent is issued, the list must be
updated within 30 days. And, the bill would apply
retroactively: within 30 days of enactment, the holders of
previously-approved biologic products must submit patent
lists. The patents required to be disclosed are those for
which the holder believes a claim of patent infringement could
reasonably be asserted. This is notably broader than the
equivalent requirement in the Hatch-Waxman Act, as it includes
manufacturing processes as well. If a